Related Experiment Video
Updated: Jun 25, 2026
07:21
Molecular and Immunologic Techniques in a Genetically Engineered Mouse Model of Gastrointestinal Stromal Tumor
Published on: May 2, 2022
Gastrointestinal stromal tumour--evolving concepts
1Airedale General Hospital, Keighley, West Yorkshire.
Summary
Gastrointestinal Stromal Tumors (GISTs) are rare mesenchymal tumors. Risk stratification and complete surgical excision are key for prognosis, with imatinib offering new hope for advanced disease.
Area of Science:
- Gastroenterology
- Oncology
- Pathology
Background:
- Gastrointestinal Stromal Tumors (GISTs) are rare mesenchymal neoplasms, comprising <1% of all primary tumors and are the most common mesenchymal tumors of the gut.
- Historically misdiagnosed due to shared histological features with smooth muscle and neurogenic tumors.
- Immunohistochemistry marker CD 117 (c-kit) has significantly improved GIST diagnosis in the last two decades.
Purpose of the Study:
- To review the current understanding of Gastrointestinal Stromal Tumors (GISTs).
- To discuss diagnostic advancements and challenges in predicting malignant potential.
- To outline current treatment strategies and emerging therapies for GISTs.
Main Methods:
- Comprehensive literature review using Medline, Pubmed, and Cochrane databases.
- Cross-referencing of identified articles to ensure thoroughness.
Main Results:
- GISTs have an estimated annual incidence of 12-14 per million population.
- Accurate risk stratification is crucial for patient prognosis and follow-up planning.
- Complete surgical excision (R0) remains the primary curative treatment modality.
Conclusions:
- Despite challenges in predicting malignant potential, risk stratification is vital for GIST management.
- Complete surgical resection is the cornerstone of curative therapy.
- Targeted molecular therapy, such as imatinib, has improved outcomes for recurrent or metastatic GIST.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:17The Tumor Microenvironment
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...